

(19)



(11)

**EP 3 640 609 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 153(4) EPC

(43) Date of publication:

**22.04.2020 Bulletin 2020/17**

(51) Int Cl.:

**G01G 3/13 (2006.01)**  
**G01N 33/53 (2006.01)**

**G01N 29/036 (2006.01)**

(21) Application number: **18838102.4**

(86) International application number:

**PCT/ES2018/070467**

(22) Date of filing: **29.06.2018**

(87) International publication number:

**WO 2019/020847 (31.01.2019 Gazette 2019/05)**

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

Designated Validation States:

**KH MA MD TN**

- **GIMENEZ ROMERO, David**  
**46010 Valencia (ES)**
- **MORAIS EZQUERRO, Sergi Beñat**  
**46022 Valencia (ES)**
- **MAQUIEIRA CATALA, Angel**  
**46022 Valencia (ES)**
- **JUSTE DOLZ, Augusto Miguel**  
**46022 Valencia (ES)**
- **GRAU GARCIA, Elena**  
**46025 Valencia (ES)**
- **PUCHADES PLA, Rosa**  
**46022 Valencia (ES)**
- **ROMAN IBORRA, Jose Andres**  
**46025 Valencia (ES)**

(30) Priority: **26.07.2017 ES 201730972**

(71) Applicants:

- **Universitat Politècnica de València**  
**46022 Valencia (ES)**
- **Instituto De Investigación Sanitaria La Fe - Funda**  
**46025 Valencia (ES)**
- **Universitat De València, Estudi General**  
**46010 València (ES)**

(74) Representative: **Carvajal y Urquijo, Isabel et al**  
**Clarke, Modet & Co.**  
**Suero de Quiñones, 34-36**  
**28002 Madrid (ES)**

(72) Inventors:

- **MARINE DO NASCIMENTO, Noelle**  
**46022 Valencia (ES)**

**(54) METHOD FOR THE DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)**

(57) The present invention relates to a method for the diagnosis of systemic lupus erythematosus (SLE), which is a diagnostic method based on an interfacial process of antigen-antibody molecular recognition, specifi-

cally between anti-Ro52 and Ro52 protein, in a piezoelectric resonator, for application in the diagnosis of autoimmune diseases such as SLE.




FIG. 2

**EP 3 640 609 A1**

**Description**Field of the Invention

5 **[0001]** The present invention relates to the technical field of the diagnosis of autoimmune diseases, and specifically to following an interfacial process of antigen-antibody molecular recognition in a piezoelectric resonator, as well as the screening of samples from autoimmune patients.

Background of the Invention

10 **[0002]** Anti-Ro/SSA antibodies are antinuclear antibodies (ANA) which are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE) and neonatal lupus. They constitute an auxiliary immunological study in the diagnosis of patients with autoimmune diseases such as lupus erythematosus (LE), or as predictors for the prognosis of some vasculitis of Sjögren's syndrome (SS). Anti-Ro antibodies were described for the first time 30 years ago in a patient with SLE with polyserositis, photosensitivity and negative for antinuclear antibodies (ANA).

15 **[0003]** SLE is the non-organ-specific autoimmune disease par excellence, since the body produces a number of antibodies (Ab) targeting its own cellular structures, which ultimately results in inflammatory lesions of multiple organs and systems. SLE is the disease that is most associated with the Ro antigen (anti-Ro).

20 **[0004]** The Ro antigen is a ribonucleoprotein made up of RNA and a protein portion which is especially located in the cell cytoplasm (hence the name scRNP, small cytoplasmic ribonucleoproteins). In the protein portion there are at least four different antigen polypeptides with sizes ranging between 52 (Ro52) and 60kD (Ro60), capable of reacting with an anti-Ro monospecific serum.

25 **[0005]** With regard to the quantitative methods for diagnosis, several assays have been developed for the determination of autoantibodies, including ELISA, immunoblot immunoassays, multiple flow immunoassay and protein arrays. The key advantages of these assays are that they are easy to use, flexible and low-cost. However, the main limitation refers to the low sensitivity, which limits the determination of extremely low concentrations of circulating serum antibodies. Therefore, the development of highly sensitive biosensors is of enormous interest for determining autoantibodies at very low concentrations.

30 **[0006]** The quartz crystal microbalance (QCM) technique has been used extensively as a biosensor because it works well, is highly sensitive and presents low limits of detection, offering excellent advantages over conventional detection techniques. In particular, quartz crystal microbalances with dissipation (QCM-D) present significant advantages in relation to sensitivity. Furthermore, QCM-D is appealing due to the response of the sensor in the form of variations in the dissipation factor ( $\Delta D$ ) which is related to viscoelasticity, which in turn is associated with structural changes in the film adhered to the QCM-D transducer. This adds complementary information in relation to structural interactions between probe and target, showing a high potential for diagnosing and predicting autoimmune diseases such as SLE. These biosensors operate under the principle that a change in mass resulting from the interaction between the antibody and its respective antigen can be determined directly.

35 **[0007]** Patent US5501986A describes a method for detecting an analyte (proteins, hormones, enzymes, antibodies, carbohydrates or nucleic acids) in a sample using QCM, measuring the change in resonance frequency and correlating the change in frequency with the amount of analyte in the sample. However, the method only relates the presence of an analyte with a single variable.

40 **[0008]** Common measurements in piezoelectric experiments correspond to surface concentration and reaction time measurements, without taking into account the viscoelastic properties of the adhered layer. As a result, transition states cannot be detected by this conventional measurement methodology during surface processes because the monitored signal cannot be separated out. To solve this problem, the simultaneous measurement of resonance frequency ( $f$ ) (adhered mass) and the dissipation factor ( $D$ ) (viscoelastic properties) were introduced in the new piezoelectric sensors. Interfacial processes can thereby be analyzed as a function of the nature of the surface thereof. The major problem with this approach is that it does not directly introduce the measurement time, therefore it cannot be measured in situ and the temporal analysis of the monitored process is furthermore made more complex.

45 **[0009]** One example is patent WO2008114003A1, which describes a method and apparatus for detecting the presence and/or amount of an oligomer analyte (antibody) in a sample by means of a piezoelectric biosensor, wherein ratios between different variables such as resonance frequency and the dissipation factor are established. This invention relates to the detection of certain diseases, in particular Alzheimer's.

50 **[0010]** Use of a function  $(-df/dD)$  which allows introducing the time factor in the structural study of the interface monitored by QCM-D has recently been published in Biosensors & Bioelectronics 2017, 90, 166. However, this function has two clear limitations: its interpretation implies highly skilled personnel, and it is not very sensitive, so it has little discrimination capacity.

Description of the Invention

**[0011]** The present invention solves the problems existing in the state of the art by means of a method for the diagnosis of autoimmune diseases in a human. Said method is based on the measurement in a piezoelectric resonator of the ratio between different variables, such as surface concentration and the quality factor, by means of the function  $d\Delta\Gamma/d\Delta Q$  of an interfacial process of antigen-antibody molecular recognition for screening samples from autoimmune patients.

**[0012]** Function  $d\Delta\Gamma/d\Delta Q$  monitors structural changes involved in the deposition of a reactive species on the surface of a piezoelectric crystal. Certain approaches are needed for the clear interpretation of its meaning:

**[0013]** The acoustic response of a piezoelectric sensor (of density " $\rho_0$ ", thickness " $h_0$ " and elastic shear modulus " $\mu_0$ ") coated with a viscoelastic film (of density " $\rho_1$ ", thickness " $h_1$ ", shear viscosity " $\eta_1$ " and elastic shear modulus " $\mu_1$ ") immersed in a Newtonian fluid (of shear viscosity " $\eta_3$ " and viscous penetration depth " $\delta_3$ ") is modeled by means of the following expressions:

$$\Delta\Gamma \approx \frac{A\sqrt{\rho_0\mu_0}}{2f^2} \frac{1}{2\pi\rho_0h_0} \left[ \frac{\eta_3}{\delta_3} + h_1\rho_1w - 2h_1\left(\frac{\eta_3}{\delta_3}\right)^2 \frac{\eta_1w^2}{\mu_1^2 + w^2\eta_1^2} \right] \quad (1)$$

$$\Delta Q \approx -\frac{D_0}{2\pi f\rho_0h_0Q_0} \left[ \frac{\eta_3}{\delta_3} + 2h_1\left(\frac{\eta_3}{\delta_3}\right)^2 \frac{\mu_1w}{\mu_1^2 + w^2\eta_1^2} \right] \quad (2)$$

wherein "Q" is the quality factor, "D" is the dissipation factor and "f" is the resonance frequency of the piezoelectric sensor (Figure 1).

**[0014]** When considering a pure elastic film ( $\eta_1 \rightarrow 0$ ) and accordingly:

$$\Delta\Gamma \approx \frac{A\sqrt{\rho_0\mu_0}}{2f^2} \frac{1}{2\pi\rho_0h_0} \left[ \frac{\eta_3}{\delta_3} + h_1\rho_1w \right] \quad (3)$$

$$\Delta Q \approx -\frac{D_0}{2\pi f\rho_0h_0Q_0} \left[ \frac{\eta_3}{\delta_3} + 2h_1\left(\frac{\eta_3}{\delta_3}\right)^2 \frac{w}{\mu_1} \right] \quad (4)$$

by deriving both expressions as a function of monitoring time (t), the following is obtained:

$$\frac{d\Delta\Gamma}{dt} \approx \frac{A\sqrt{\rho_0\mu_0}}{2f^2} \frac{1}{2\pi\rho_0h_0} \frac{d(h_1\rho_1w)}{dt} \stackrel{w \rightarrow cte}{\approx} \frac{A\sqrt{\rho_0\mu_0}}{2f^2} \frac{w}{2\pi\rho_0h_0} \frac{d(h_1\rho_1)}{dt} \quad (5)$$

$$\frac{d\Delta Q}{dt} \approx -\frac{D_0}{2\pi f\rho_0h_0Q_0} 2\left(\frac{\eta_3}{\delta_3}\right)^2 \frac{d\left(\frac{h_1w}{\mu_1}\right)}{dt} \stackrel{w \rightarrow cte}{\approx} -\frac{wD_0}{2\pi f\rho_0h_0Q_0} 2\left(\frac{\eta_3}{\delta_3}\right)^2 \frac{d\left(\frac{h_1}{\mu_1}\right)}{dt} \quad (6)$$

and by dividing them ( $(\partial\Delta\Gamma/\partial t)/(\partial\Delta Q/\partial t)$ ), function  $\partial\Delta\Gamma/\partial\Delta Q$  (8) is obtained:

$$\frac{d\Delta\Gamma}{d\Delta Q} = \frac{\frac{d\Delta\Gamma}{dt}}{\frac{d\Delta Q}{dt}} \approx -\frac{A\sqrt{\rho_0\mu_0}}{2f} \frac{Q_0\delta_3^2}{D_0 2\eta_3^2} \frac{d(h_1\rho_1)}{dt} = -\frac{A\sqrt{\rho_0\mu_0}}{2f} \frac{Q_0\delta_3^2}{D_0 2\eta_3^2} \frac{d(h_1\rho_1)}{d\left(\frac{h_1}{\mu_1}\right)} \quad (7)$$

$$= -\frac{A\sqrt{\rho_0\mu_0}}{2f} \frac{Q_0\delta_3^2}{D_0 2\eta_3^2} \left( h_1 \frac{d(\rho_1)}{d\left(\frac{h_1}{\mu_1}\right)} + \rho_1 \frac{d(h_1)}{d\left(\frac{h_1}{\mu_1}\right)} \right) \stackrel{h_1 \rightarrow cte}{\approx} -\frac{A\sqrt{\rho_0\mu_0}}{2f} \frac{Q_0\delta_3^2}{D_0 2\eta_3^2} \frac{d\rho_1}{d\left(\frac{1}{\mu_1}\right)}$$

$$\frac{d\Delta\Gamma}{d\Delta Q} \approx -\frac{A\sqrt{\rho_0\mu_0}}{2f} \frac{Q_0\delta_3^2}{D_0 2\eta_3^2} \frac{d\rho_1}{d\left(\frac{1}{\mu_1}\right)} \quad (8)$$

**[0015]** Equation (8) shows how function  $d\Delta\Gamma/d\Delta Q$  is directly proportional to the variation of the density of the film adhered to the sensor surface with respect to the inverse of its viscoelastic properties. Therefore, if the film adhered to a piezoelectric surface is modified only by one process, the value of the function  $\partial\Delta\Gamma/\partial\Delta Q$  will remain constant over the

$$d\rho_1/d\left(\frac{1}{\mu_1}\right)$$

transformation time, given that function: will be constant.

**[0016]** In that case, each adhered species will regularly modify the viscoelastic properties of the film monitored by the piezoelectric sensor. However, if the monitored transformation corresponds to multiple parallel or consecutive processes, the function  $d\Delta\Gamma/d\Delta Q$  will vary over time presenting n-1 maximums, wherein n corresponds to the number of species constituted during the transformation process. Therefore, said function allows unequivocally characterizing the transformation processes of the films adhered on piezoelectric materials by both their evolution over time and by the time values they have.

**[0017]** Therefore, a first aspect of the invention is a method for the diagnosis of autoimmune diseases in a human comprising two steps:

- (a) incubating a sample obtained from said human in a piezoelectric resonator comprising a protein antigen immobilized on the surface of the resonator and determining the value of the function  $d\Delta\Gamma/d\Delta Q$  described in function (8), and
- (b) performing the diagnosis of autoimmune diseases by determining the maximum value of  $d\Delta\Gamma/d\Delta Q$ , where the diagnosis is positive when the maximum is greater than a cutoff value of 600 ng/cm<sup>2</sup>.

**[0018]** In another aspect of the invention, the autoimmune diseases for which this method is suitable include Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and neonatal lupus erythematosus (NLE).

**[0019]** In another aspect of the invention, the protein antigen used for the diagnosis of the aforementioned diseases is the Ro protein antigen (anti-Ro). Specifically, the protein antigen is Ro52 since the conformational changes implied by molecular recognition are very different between patients and healthy subjects.

**[0020]** Systemic lupus erythematosus (SLE) is the disease which is most associated with anti-Ro, with a reported average positivity of 27.7%, which increases up to 45 to 50% when analyzed by ELISA. In the case of a late onset LE (over 50 years old), positivity is 92%.

**[0021]** Furthermore, anti-Ro is an important disease marker in neonatal lupus erythematosus (NLE), since over 90% of mothers and their babies express it, although the prevalence of NLE in anti-Ro mothers is 1%. Anti-Ro is also present in 70 to 88% of patients with primary Sjögren's syndrome (SS) and in 10 to 50% of secondary cases.

**[0022]** In another aspect of the invention, the sample incubated in step (a) of the method is obtained from the blood serum of the patient for whom the diagnosis of the aforementioned autoimmune diseases is to be performed.

#### Brief Description of Figures

**[0023]**

Figure 1. Representation of the geometry of a piezoelectric crystal coated with a viscoelastic film (general depiction of a concept that is known in the state of the art).

Figure 2. Graphic representation of function  $d\Delta\Gamma/d\Delta Q$  over time during the interaction of Ro52 protein with autoantibodies coming from anti-Ro+ autoimmune patients (a) and healthy individuals (b).

5

## Description of Embodiments

### Example 1. Study of the interaction antibody anti-Ro52/Ro52 protein.

10 **[0024]** The chemical immobilization of specific autoantigens in the piezoelectric resonator and the determination of circulating autoantibodies were performed.

**[0025]** Ro52 protein was immobilized by covalent anchoring, forming a self-assembled monolayer. The monolayer was created by submerging the piezoelectric surface for 16 h in a 10 mM mercaptopropionic acid solution and subsequent activation by 10 mM EDC/NHS for 60 min. Next, the surface was treated with 5 mM carbonyldiimidazole for 60 min. Then 15 100  $\mu\text{L}$  of Ro52 protein (33 mg/L) were dispensed on the sensor surface, being incubated for 60 min. Finally, the free active residues were blocked by means of treating the sensor surface with an aqueous solution containing EDTA, BSA and Tween 20 at 0.05%, pH 8.5.

**[0026]** The antibodies were purified from the serum of anti-Ro+ patients.

20 **[0027]** Next, the variation of the surface concentration and the quality factor during the selective interaction of autoantigens with specific autoantibodies present in a PBS1x solution was recorded using a piezoelectric sensor.

**[0028]** Subsequently, function  $\partial\Delta\Gamma/\partial\Delta Q$ , wherein " $\Gamma$ " is the surface concentration and " $Q$ " is the quality factor, during the studied molecular recognition process was calculated (Figure 2a). Figure 2a shows the fingerprint characteristic of the molecular recognition process, presenting a maximum value at 3,000 ng/cm<sup>2</sup> at 1,000 seconds. Therefore, as described above, this function shows that the monitored process corresponds to cooperative binding. The antibodies 25 bind the antigen by means of a specific epitope-paratope interaction, for the Fc fragment of these antibodies to subsequently be recognized by the PRY-SPRY domain of Ro52 protein. This experiment demonstrates the use of the function to monitor transition states and molecular recognition patterns, establishing reaction pathways of the studied process.

### Example 2. Study of the application of function $d\Delta\Gamma/d\Delta Q$ in healthy patients and anti-Ro+ autoimmune patients.

30 **[0029]** To demonstrate the goodness of use of function  $d\Delta\Gamma/d\Delta Q$  for the discrimination of patients with autoimmune diseases, the molecular recognition of anti-Ro52 antibodies from anti-Ro+ autoimmune patients and healthy individuals was studied. As shown in Figure 2, the antibodies of both populations show a similar recognition behavior when represented over time.

35 **[0030]** The pattern shown is a function with a peak shape having a maximum value around 1,000 seconds. Therefore, both processes have one and the same cooperative reaction mechanism. However, the antibodies from anti-Ro+ patients have a maximum value close to 3,000 ng/cm<sup>2</sup>.

**[0031]** This characteristic pattern remains unchanged when solutions containing anti-Ro52 antibodies of a population of 130 anti-Ro+ autoimmune patients are analyzed. In contrast, when the serum of healthy patients is analyzed, the antibody recognition pattern presents a maximum value at 500 ng/cm<sup>2</sup>.

40 **[0032]** Therefore, function  $\partial\Delta\Gamma/\partial\Delta Q$  allows unequivocally discriminating anti-Ro+ patients by establishing a cutoff value at 600 ng/cm<sup>2</sup>, identifying characteristic recognition patterns.

## 45 Claims

1. A method for the diagnosis of systemic lupus erythematosus (SLE) in a human, **characterized in that** it comprises:

50 (a) incubating a sample obtained from said human in a piezoelectric resonator comprising a protein antigen immobilized on the surface of the resonator and determining the value of the formula

$$55 \frac{d\Delta\Gamma}{d\Delta Q} \approx - \frac{A\sqrt{\rho_0\mu_0}}{2f} \frac{Q_0\delta_3^2}{D_0 2\eta_3^2} \frac{d\rho_1}{d\left(\frac{1}{\mu_1}\right)}$$

with respect to time, wherein " $\Gamma$ " is the surface concentration and " $Q$ " the quality factor, " $A$ " is surface area of

## EP 3 640 609 A1

the resonator, " $\rho_0$ " is the density", " $D_0$ " is the dissipation factor, " $f$ " is the resonance frequency and " $\mu_0$ " is the elastic shear modulus of the piezoelectric sensor, " $\rho_1$ " is the density and " $\mu_1$ " is the elastic shear modulus of a viscoelastic film coating the sensor, " $\eta_3$ " is the shear viscosity and " $\delta_3$ " is the viscous penetration depth of a Newtonian fluid in which the film is immersed, and

5 (b) performing the diagnosis of systemic lupus erythematosus (SLE) by determining the maximum value of  $d\Delta\Gamma/d\Delta Q$ , wherein the diagnosis is positive when the maximum is greater than a cutoff value of 600 ng/cm<sup>2</sup>.

2. The method according to claim 1, **characterized in that** the protein antigen is Ro.

10 3. The method according to claim 1, **characterized in that** the protein antigen is Ro52.

4. The method according to any of claims 1 to 3, **characterized in that** said sample is blood serum.

15

20

25

30

35

40

45

50

55





FIG. 1

a)



b)




FIG. 2

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/ES2018/070467

5

## A. CLASSIFICATION OF SUBJECT MATTER

**See extra sheet**

According to International Patent Classification (IPC) or to both national classification and IPC

10

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
G01G, G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

15

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

INVENES, EPODOC, WPI, BIOSIS, MEDLINE, XPESP, TXPUS, XPI3E

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

20

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DO NASCIMENTO NOELLE M et al. Label-free piezoelectric biosensor for prognosis and diagnosis of Systemic Lupus Erythematosus. Biosensors and Bioelectronics. 2016, vol. 90, pp. 166-173, ISSN 0956-5663, <DOI: 10.1016/j.bios.2016.11.004>, especially pages 167-169; figure 2b.	1-4
A	DO NASCIMENTO NOELLE M. The Ro/SSA Complex in Systemic Lupus Erythematosus Patients. Ph.D. Thesis. Universitat Politècnica de València. Department of Chemistry, 02/2017 [on line] [retrieved the 06/11/2018]. Retrieved from Internet <URL: <a href="https://www.tdx.cat/handle/10251/80534?locale-attribute=es">https://www.tdx.cat/handle/10251/80534?locale-attribute=es</a> >, especially page 17.	1-4
A	WO 2008114003 A1 (INVERNESS MEDICAL SWITZERLAND ET AL.), 25/09/2008, the whole document.	1-4

40

 Further documents are listed in the continuation of Box C. See patent family annex.

45

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance.	
"E" earlier document but published on or after the international filing date	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"O" document referring to an oral disclosure use, exhibition, or other means.	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other documents, such combination being obvious to a person skilled in the art
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

50

Date of the actual completion of the international search  
07/11/2018Date of mailing of the international search report  
(08/11/2018)

55

Name and mailing address of the ISA/

Authorized officer  
J. Collado MartínezOFICINA ESPAÑOLA DE PATENTES Y MARCAS  
Paseo de la Castellana, 75 - 28071 Madrid (España)  
Facsimile No.: 91 349 53 04

Telephone No. 91 3493095

Form PCT/ISA/210 (second sheet) (January 2015)

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/ES2018/070467

5

C (continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of documents, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DIXON MATTHEW C. Quartz crystal microbalance with dissipation monitoring: enabling real-time characterization of biological materials and their interactions.. Journal of Biomolecular Techniques. 2008, vol. 19, no. 3, pp. 151-158, ISSN 1943-4731, the whole document.	1-4
A	WO 9635103 A1 (RODAHL MICHAEL ET AL.) 07/11/1996, the whole document.	1-4

10

15

20

25

30

35

40

45

50

55

Form PCT/ISA/210 (continuation of second sheet) (January 2015)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/ES2018/070467

Information on patent family members

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Patent document cited in the search report	Publication date	Patent family member(s)	Publication date
WO2008114003 A1	25.09.2008	US2010087011 A1 EP2122355 A1	08.04.2010 25.11.2009
----- WO9635103 A1	07.11.1996	US6006589 A SE504199 C2 SE9501653L L EP0775295 A1 EP0775295 B1 DE69610183T T2 AU5783796 A	28.12.1999 05.11.1996 05.11.1996 28.05.1997 06.09.2000 21.06.2001 21.11.1996
-----	-----	-----	-----

INTERNATIONAL SEARCH REPORT

International application No.

PCT/ES2018/070467

5

**CLASSIFICATION OF SUBJECT MATTER**

*G01G3/13* (2006.01)  
*G01N29/036* (2006.01)  
*G01N33/53* (2006.01)

10

15

20

25

30

35

40

45

50

55

Form PCT/ISA/210 (extra sheet) (January 2015)

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- US 5501986 A [0007]
- WO 2008114003 A1 [0009]

**Non-patent literature cited in the description**

- *Biosensors & Bioelectronics*, 2017, vol. 90, 166 [0010]

专利名称(译)	诊断系统性红斑狼疮 ( SLE ) 的方法		
公开(公告)号	<a href="#">EP3640609A1</a>	公开(公告)日	2020-04-22
申请号	EP2018838102	申请日	2018-06-29
[标]申请(专利权)人(译)	UNIV VALENCIA ESTUDI一般		
申请(专利权)人(译)	Universität大学POLITÈCNICA瓦伦西亚 Universität大学瓦伦西亚 , ESTUDI GENERAL		
当前申请(专利权)人(译)	Universität大学POLITÈCNICA瓦伦西亚 Universität大学瓦伦西亚 , ESTUDI GENERAL		
[标]发明人	MARINE DO NASCIMENTO NOELLE GIMENEZ ROMERO DAVID MORAIS EZQUERRO SERGI BENAT MAQUIEIRA CATALA ANGEL JUSTE DOLZ AUGUSTO MIGUEL GRAU GARCIA ELENA PUCHADES PLA ROSA ROMAN IBORRA JOSE ANDRES		
发明人	MARINE DO NASCIMENTO, NOELLE GIMENEZ ROMERO, DAVID MORAIS EZQUERRO, SERGI BEÑAT MAQUIEIRA CATALA, ANGEL JUSTE DOLZ, AUGUSTO MIGUEL GRAU GARCIA, ELENA PUCHADES PLA, ROSA ROMAN IBORRA, JOSE ANDRES		
IPC分类号	G01G3/13 G01N29/036 G01N33/53		
CPC分类号	G01G3/13 G01G3/16 G01N29/036 G01N33/53		
代理机构(译)	卡瓦哈尔·乌尔基霍 , ISABEL		
优先权	2017030972 2017-07-26 ES		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

用于诊断系统性红斑狼疮的方法技术领域本发明涉及一种用于诊断系统性红斑狼疮 ( SLE ) 的方法，该诊断方法是基于抗原-分子分子识别的界面过程，特别是在压电谐振器中的抗Ro52和Ro52蛋白之间的诊断方法。应用在自身免疫性疾病如SLE的诊断中。




FIG. 2